@StickyRice:Novavax's COVID-19 shot gets approval for use in teenagers in South KoreaNovavax (NASDAQ:NVAX) $Novavax(NVAX)$on Friday said its protein-based COVID-19 vaccine had received an expanded approval in South Korea for use in teenagers aged 12 to 17 years.The U.S. company's partner, SK bioscience, got a post approval change application nod from the Korean Ministry of Food and Drug Safety for the COVID shot, Nuvaxovid, NVAX said in a statement."Today's approval in South Korea is an important step in ensuring broad global access to a protein-based vaccine option," said NVAX CEO Stanley Erck.Nuvaxovid had already been given approval for use in teenagers aged 12 through 17 years in India, the European Union, Australia, Thailand and
@Lashsmith:$AMC Entertainment(AMC)$Last week the SEC of Chicago sent out tweets regarding trading halts. Also, the head of the SEC, Gary Gensler tweeted a simple quiz about trading halts, advising people to take it by the end of the month. What does this show? To me it shows it's time to get plans in place (selling prices). No one knows when this will happen, but those messages indicate something. Still holding strong ✊